Gemma Castaño-Vinyals1, Nuria Aragonés2, Beatriz Pérez-Gómez2, Vicente Martín3, Javier Llorca4, Victor Moreno5, Jone M Altzibar6, Eva Ardanaz7, Sílvia de Sanjosé8, José Juan Jiménez-Moleón9, Adonina Tardón10, Juan Alguacil11, Rosana Peiró12, Rafael Marcos-Gragera13, Carmen Navarro14, Marina Pollán2, Manolis Kogevinas15. 1. Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Electronic address: gcastano@creal.cat. 2. Environmental and Cancer Epidemiology Unit, National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; IIS Puerta de Hierro, Majadahonda, Spain. 3. Universidad de León, León, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 4. Universidad de Cantabria, Santander, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 5. IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 6. Subdirección de Salud Pública de Gipuzkoa, Donostia, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 7. Instituto de Salud Pública de Navarra, Pamplona, Navarra; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 8. IDIBELL-Catalan Institute of Oncology, L'Hospitalet de Llobregat, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 9. Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 10. Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Asturias, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 11. Centro de Investigación en Salud y Medio Ambiente (CYSMA), Universidad de Huelva, Huelva, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 12. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana FISABIO-Salud Pública, Valencia, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 13. Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology, Girona Biomedical Research Institute (IdiBGi), Girona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. 14. Department of Epidemiology, Murcia Regional Health Authority, Murcia, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain. 15. Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; School of Public Health, Athens, Greece.
Abstract
INTRODUCTION: We present the protocol of a large population-based case-control study of 5 common tumors in Spain (MCC-Spain) that evaluates environmental exposures and genetic factors. METHODS: Between 2008-2013, 10,106 subjects aged 20-85 were enrolled in 23 hospitals and primary care centres in 12 Spanish provinces including 1,112 cases with a new diagnosis of prostate cancer, 1,738 of breast cancer, 2,140 of colorectal cancer, 459 of gastro-oesophageal cancer, 559 cases with chronic lymphocytic leukaemia and 4,098 population controls frequency matched to cases by age, sex and region of residence. Participation rates ranged from 57% (stomach cancer) to 87% (CLL cases) and from 30% to 77% in controls. Participants completed a face-to-face computerized interview on sociodemographic factors, environmental exposures, occupation, medication, lifestyle, and personal and family medical history. In addition, participants completed a self-administered food-frequency questionnaire and telephone interviews. Blood samples were collected from 76% of participants while saliva samples were collected in CLL cases and participants refusing blood extractions. Clinical information was recorded for cases and paraffin blocks and/or fresh tumor samples are available in most collaborating hospitals. Genotyping was done through an exome array enriched with genetic markers in specific pathways. Multiple analyses are planned to assess the association of environmental, personal and genetic risk factors for each tumor and to identify pleiotropic effects. DISCUSSION: This study, conducted within the Spanish Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), is a unique initiative to evaluate etiological factors for common cancers and will promote cancer research and prevention in Spain.
INTRODUCTION: We present the protocol of a large population-based case-control study of 5 common tumors in Spain (MCC-Spain) that evaluates environmental exposures and genetic factors. METHODS: Between 2008-2013, 10,106 subjects aged 20-85 were enrolled in 23 hospitals and primary care centres in 12 Spanish provinces including 1,112 cases with a new diagnosis of prostate cancer, 1,738 of breast cancer, 2,140 of colorectal cancer, 459 of gastro-oesophageal cancer, 559 cases with chronic lymphocytic leukaemia and 4,098 population controls frequency matched to cases by age, sex and region of residence. Participation rates ranged from 57% (stomach cancer) to 87% (CLL cases) and from 30% to 77% in controls. Participants completed a face-to-face computerized interview on sociodemographic factors, environmental exposures, occupation, medication, lifestyle, and personal and family medical history. In addition, participants completed a self-administered food-frequency questionnaire and telephone interviews. Blood samples were collected from 76% of participants while saliva samples were collected in CLL cases and participants refusing blood extractions. Clinical information was recorded for cases and paraffin blocks and/or fresh tumor samples are available in most collaborating hospitals. Genotyping was done through an exome array enriched with genetic markers in specific pathways. Multiple analyses are planned to assess the association of environmental, personal and genetic risk factors for each tumor and to identify pleiotropic effects. DISCUSSION: This study, conducted within the Spanish Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), is a unique initiative to evaluate etiological factors for common cancers and will promote cancer research and prevention in Spain.
Authors: Lucas A Salas; Mariona Bustamante; Juan R Gonzalez; Esther Gracia-Lavedan; Victor Moreno; Manolis Kogevinas; Cristina M Villanueva Journal: Epigenetics Date: 2015 Impact factor: 4.528
Authors: M Pinto-Carbó; R Peiró-Pérez; A Molina-Barceló; M Vanaclocha-Espi; J Alguacil; G Castaño-Vinyals; C O'Callaghan-Gordo; E Gràcia-Lavedan; B Pérez-Gómez; V Lope; N Aragonés; A J Molina; T Fernández-Villa; L Gil-Majuelo; P Amiano; T Dierssen-Sotos; I Gómez-Acebo; M Guevara; C Moreno-Iribas; M Obón-Santacana; M M Rodríguez-Suárez; I Salcedo-Bellido; A Delgado-Parrilla; R Marcos-Gragera; M D Chirlaque; M Kogevinas; M Pollán; D Salas Journal: PLoS One Date: 2021-05-12 Impact factor: 3.240
Authors: Marta Solans; Sílvia Fernández-Barrés; Dora Romaguera; Yolanda Benavente; Rafael Marcos-Gragera; Esther Gracia-Lavedan; Laura Costas; Claudia Robles; Eva Gonzalez-Barca; Esmeralda de la Banda; Esther Alonso; Marta Aymerich; Elias Campo; Javier Llorca; Guillermo Fernández-Tardón; Rocío Olmedo-Requena; Eva Gimeno; Gemma Castaño-Vinyals; Nuria Aragonés; Manolis Kogevinas; Marina Pollán; Silvia de Sanjose; Pilar Amiano; Delphine Casabonne Journal: Int J Environ Res Public Health Date: 2021-05-20 Impact factor: 3.390